Article Details

Alnylam, awaiting key study data, builds case for its next rare disease drug | BioPharma Dive

Retrieved on: 2022-01-21 17:21:21

Tags for this article:

Click the tags to see associated articles and topics

Alnylam, awaiting key study data, builds case for its next rare disease drug | BioPharma Dive. View article details on HISWAI: https://www.biopharmadive.com/news/alnylam-vutrisiran-ttr-18-month-results/617516/

Excerpt

Dive Insight: For many years, the only treatments for TTR — a rare and potentially deadly disease — were liver transplants and a generic pill that ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up